Activity of CYP3A and Genotypes of CYP3A5- and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients.

Trial Profile

Activity of CYP3A and Genotypes of CYP3A5- and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2010

At a glance

  • Drugs Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top